Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810979 · ClinicalTrials.gov registry record · Phase 2
Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia
A Phase 2 study, sponsored by Response Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT00810979 is a Phase 2 study that has completed, run by Response Pharmaceuticals. The registered enrollment target is 133 participants.
The verdict
NCT00810979, a Phase 2 study, has completed, sponsored by Response Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.
Interventions
- OTHER Placebo
- DRUG Statin
- DRUG SLx-4090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00810979
The ClinicalTrials.gov registry entry for NCT00810979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Response Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00810979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00810979 about?
NCT00810979 is a clinical study titled "Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia". The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.
What is the current status of trial NCT00810979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2009-01. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00810979?
The interventions under investigation include: Placebo (OTHER), Statin (DRUG), SLx-4090 (DRUG).
Who is sponsoring clinical trial NCT00810979?
This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.